FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. What is presented is a recovered human integrin α5β1 monoclonal antibody. The antibody is characterised by the fact that it contains 6 CDR, 3 CDR from a light chain and 3 CDR from a heavy chain. A nucleic acid (NA) coding the antibody according to the invention, an expression vector containing a NA molecule, a host cell containing the vector, and a method for preparing the antibody on the basis of the cell are described. There are disclosed: a composition and a method for growth inhibition of the tumour cells expressing human integrin α5β1 on the basis of the antibody. What is described is a version of the method for growth inhibition of the tumour cells expressing human integrin α5β1 using the composition.
EFFECT: invention provides the new antibodies with high (approximately nm, as measured by FACS) binding affinity for human integrin α5β1 that can find application in medicine in therapy of the tumours mediated by integrin α5β1 expression.
13 cl, 36 dwg, 3 tbl, 11 ex
Title |
Year |
Author |
Number |
ANTI-SIRPα ANTIBODY AND USE THEREOF |
2021 |
- U, Chzhenkhua
- Ne, Lej
- Mej, Syaofen
- Van, Khajbin
- Chen, Tszyuan
- Li, Na
- Van, Syaotsze
- Chzhou, Yatsion
- Chen, Yao
- Tszyan, Mejchzhu
|
RU2822496C1 |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2013 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2599417C2 |
ANTI c-Met RECEPTOR PROTEIN ANTIBODIES |
2011 |
- Khultberg Anna
- Sonders Majkl
- De Khard Jokhannes
- Festens Els
- De Jonge Natali
- Mikeli Paulo
- Baziliko Kristina
- Drajer Torsten
|
RU2608644C2 |
HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2016 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanyuj
- Selbi Mark Dzh.
- Chen Bin
- Kardarelli Zhozefin M.
|
RU2732924C2 |
ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION |
2005 |
- Kardarelli Zhozefin M.
- Vitte Ehlison
- Srinivasan Mokhan
|
RU2412202C2 |
HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR PROGRAMMED CELL DEATH 1 (PD1) PROTEIN AND METHODS OF TREATING CANCER WITH USING ANTI-PD1 ANTIBODIES EITHER INDIVIDUALLY, OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
- Khuan Khajchun'
|
RU2494107C2 |
HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED DEATH 1 (PD-1) PROTEIN AND CANCER TREATMENT METHOD USING ANTI-PD-1-ANTIBODIES SEPARATELY OR COMBINED WITH OTHER IMMUNOTHERAPEUTIC AGENTS |
2006 |
- Korman Alan Dzh.
- Srinivasan Mokhan
- Van Chanjuj
- Selbi Mark Dzh.
- Chehn' Bin
- Kardarelli Zhozefin M.
|
RU2406760C2 |
MEDICINAL AGENT CONTAINING PHOSPHOLIPASE D4 ANTIBODY |
2014 |
- Yamazaki Tomokhide
- Endo Mayuki
- Isida Kodzi
|
RU2709741C2 |
RECOVERED IP-10 ANTIBODY, IMMUNOCONJUGATE AND BIOSPECIFIC MOLECULE THEREOF, COMPOSITIONS THEREOF, METHOD OF TREATING (VERSIONS), CODING MOLECULE OF NUCLEIC ACID, RELATIVE EXPRESSION VECTOR, HOST CELL AND HYBRIDOMA |
2004 |
- Kardarelli Dzhozefin M.
- Deshpande Shrikant
- Khuan Khajchun'
- Kirstehd Gans S.
- Lejn Tomas Eh.
- Lju Majkl T.
- Passmor Dehvid
- Rangan Vangipuram S.
- Srinivasan Mokhan
- Van Chan'Juj
|
RU2486199C2 |
ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD |
2019 |
- Kim, Bongcheol
- Kim, Wonkyum
- Kim, Dong Sik
- Lee, Jae-Keun
- Yoon, Jeongwon
- Chung, Junho
- Jin, Junyeong
|
RU2785436C2 |